biostudies-literatureChoueiri TKNCATS NIH HHSNIMHD NIH HHSNCI NIH HHS100445https://www.ebi.ac.uk/biostudies/studies/S-EPMC9925160biostudies-literatureUnknown19<h4>Background</h4>Breakthrough SARS-CoV-2 infections following vaccination against COVID-19 are of international concern. Patients with cancer have been observed to have worse outcomes associated with COVID-19 during the pandemic. We sought to evaluate the clinical characteristics and outcomes of patients with cancer who developed breakthrough SARS-CoV-2 infections after 2 or 3 doses of mRNA vaccines.<h4>Methods</h4>We evaluated the clinical characteristics of patients with cancer who developed breakthrough infections using data from the multi-institutional COVID-19 and Cancer Consortium (CCC19; NCT04354701). Analysis was restricted to patients with laboratory-confirmed SARS-CoV-2 diagnosed in 2021 or 2022, to allow for a contemporary unvaccinated control population; potential differencesLancet regional health. AmericasBreakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium.PMC9925160P50 MD017341P30 CA046592P30 CA068485R21 CA242044T32 CA236621UL1 TR001425UL1 TR000445Singh SRKde Lima Lopes GYared FGatson NTNHsu CYO'Connor TELabaki CSchmidt ALVikas PDel Prete SNanchal RGriffiths EAKlein EJSingh HFaller BShyr YMavromatis BHZaren HAPuc MWu UDutra MSRubinstein SMJoshi MJani CFarmakiotis DWise-Draper TMMishra SBakouny ZHalabi SWeissmann LBRivera DRQuinn RNonato TKRussell KChoueiri TKBlau SBerg SFriese CRReuben DYHwang CAccordino MKPanagiotou OAWarner JLMcKay RRfalseBreakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium.<h4>Background</h4>Breakthrough SARS-CoV-2 infections following vaccination against COVID-19 are of international concern. Patients with cancer have been observed to have worse outcomes associated with COVID-19 during the pandemic. We sought to evaluate the clinical characteristics and outcomes of patients with cancer who developed breakthrough SARS-CoV-2 infections after 2 or 3 doses of mRNA vaccines.<h4>Methods</h4>We evaluated the clinical characteristics of patients with cancer who developed breakthrough infections using data from the multi-institutional COVID-19 and Cancer Consortium (CCC19; NCT04354701). Analysis was restricted to patients with laboratory-confirmed SARS-CoV-2 diagnosed in 2021 or 2022, to allow for a contemporary unvaccinated control population; potential differences2023-01-01T00:00:00Z2023 Mar2026-05-28T20:40:53.511Z2024-11-20T11:01:02.222ZS-EPMC99251603681859510.1016/j.lana.2023.100445